Skip to main content

4 Result(s)

within Rolf P. Kreutz Remove this filter

and

  1. No Access

    Article

    The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial

    Adverse drug events (ADEs) account for a significant mortality, morbidity, and cost burden. Pharmacogenetic testing has the potential to reduce ADEs and inefficacy. The objective of this INGENIOUS trial (NCT02...

    Michael T. Eadon, Marc B. Rosenman, Pengyue Zhang… in The Pharmacogenomics Journal (2023)

  2. No Access

    Article

    Intensified P2Y12 inhibition for high-on treatment platelet reactivity

    High on treatment platelet reactivity (HPR) during treatment with clopidogrel has been consistently found to be strong risk factor for recurrent ischemic events after percutaneous coronary intervention (PCI). ...

    Fakilahyel S. Mshelbwala, Daniel W. Hugenberg… in Journal of Thrombosis and Thrombolysis (2020)

  3. No Access

    Article

    A comprehensive review and meta-analysis of risk factors for statin-induced myopathy

    To aid prescribers in assessing a patient’s risk for statin-induced myopathy (SIM), we performed a comprehensive review of currently known risk factors and calculated aggregated odds ratios for each risk facto...

    Khoa A. Nguyen, Lang Li, Deshun Lu… in European Journal of Clinical Pharmacology (2018)

  4. No Access

    Article

    Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease

    Factor XIII (FXIII) is necessary for cross linking of fibrin strands and generation of stable fibrin clot. FXIII Val34Leu is a common genetic single nucleotide polymorphism that has been associated with accele...

    Rolf P. Kreutz, Abbas Bitar, Janelle Owens… in Journal of Thrombosis and Thrombolysis (2014)